TMO - Thermo Fisher Scientific Inc
The world leader in scientific instrumentation and life science services, supplying laboratories and pharmaceutical manufacturers with the tools to accelerate research.
Finlify Score
51.9 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$609.82
+1.10%
52W Range
$435.27 - $647.00
Market Cap
$228.2B
+1.1%Compared to previous day
2026 Q1 Revenue
$11.0B
-9.9%Changes from last reporting quarter
2026 Q1 EPS
$4.43
Diluted shares
Analyst Rating
36 analysts in latest ratings feed
RSI
38.6
<40 oversold
2Y Range Position
86%
-5.7% from high / +58.2% from low
Beta
0.87
Relative to market benchmark
MACD
-4.52
MACD line 8.25 / signal line 12.77
Fundamental Trend
Growth 30.1Financial Health
Quality 57.9Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
HOLD51.9 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $11.0B-9.9% | $12.2B+9.8% | $11.1B+2.5% | $10.9B+4.7% |
| Gross Profit | - | - | - | - |
| Operating Income | $1.9B-17.4% | $2.3B+16.2% | $1.9B+5.7% | $1.8B+6.9% |
| Net Income | $1.7B-15.9% | $2.0B+21.5% | $1.6B+0.2% | $1.6B+6.8% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Aug 1, 2026
Finlify's signal for TMO is HOLD, with a Finlify Score of 48.6/100, suggesting a neutral stance based on a mix of contributing factors. The overall score appears to reflect a balance between stronger accumulation and moderate financial quality, offset by weaker fundamental trends and relative strength.
Technical
The Accumulation / Volume score of 79.1/100 indicates strong buying interest, which may have contributed to recent positive momentum, with a 20-day return of 12.4% and a 60-day return of 24.7%. However, the Relative Strength score of 42.7/100 appears moderate, and an RSI(14) of 70.3 suggests the asset may be approaching overbought conditions. The asset is currently -9.8% from its 52-week high.
Fundamentals
The Fundamental Trend score of 30.1/100 appears relatively weak, while the Financial Quality score of 57.9/100 suggests moderate underlying financial health. Valuation multiples, including a P/E of 31.7x, P/B of 4.1x, and P/S of 4.8x, may indicate a premium valuation. The asset's Beta of 0.8 suggests it has historically exhibited lower volatility compared to the broader market, and it offers a modest dividend yield of 0.33%.
Macro Context
The macro environment, characterized by CPI YoY at 3.7% and Core PCE at 3.3%, suggests persistent inflationary pressures, which could influence future interest rate policy. A 10Y Treasury Yield of 4.7% and a positive yield spread of 0.5% (10Y-2Y) may indicate a higher cost of capital environment, potentially impacting growth-oriented sectors like Life Sciences Tools & Services.
Key Risks
- The Fundamental Trend score of 30.1/100 suggests potential underlying weakness in the asset's business momentum.
- An RSI(14) of 70.3, combined with recent strong returns, indicates the asset may be technically overextended in the short term.
- Valuation multiples such as a P/E of 31.7x and P/S of 4.8x may suggest a premium valuation.